Table 15:
Initial Treatment Distribution, With and Without Prolaris Cycle Cell Progression Test
| Treatment | Reference Scenario: Without CCP, % | New Scenario: With CCP | |||
|---|---|---|---|---|---|
| Base Case (Shore et al 201656), % | Change From Reference Scenario, % | Best Case Scenario (Crawford et al 201455), % | Change From Reference Scenario, % | ||
| Active surveillance or watchful waiting | 33.7 | 37.0 | 52.4 | ||
| Watchful waiting | 8.4 | 8.4 | 0 | 8.4 | 0 |
| Active surveillance | 25.3 | 28.6a | 3.3 | 44.0b | 18.7 |
| Radiation therapy | 38.3 | 36.4c | –1.9 | 27.5d | –10.8 |
| Radical prostatectomy | 27.9 | 26.6e | –1.4 | 20.0f | –7.9 |
| Total | 100 | 100 | 100 | ||
Abbreviations: CCP, cycle cell progression test.
a
28.6% = 25.3% * (1–24.2%) + (38.3% + 27.9%) * 14.2%
b
44.0% = 25.3% * (1–23.4%) + (38.3% + 27.9%) * 37.2%
c
36.4% = 38.3% * (1–14.2%) + 25.3% * 24.2% * 38.3% / (38.3% + 27.9%)
d
27.5% = 38.3% * (1–37.2%) + 25.3% * 23.4% * 38.3% / (38.3% + 27.9%)
e
26.6% = 27.9% * (1–14.2%) + 25.3% * 24.2% * 27.9% / (38.3% + 27.9%)
f
20.0% = 27.9% * (1–37.2%) + 25.3% * 23.4% * 27.9% / (38.3% + 27.9%)